Regulatory & Product Strategy / Service
Product positioning, claims feasibility, evidence strategy, and regulatory considerations for the women's health category.
The Work
Women's health is not one regulatory category. A single brand can span prescription and OTC drugs, medical devices, dietary supplements, diagnostics, and digital tools, often within the same therapeutic area: menopause, fertility, pelvic health, hormone support, breast health, perimenopause symptom management. Each line carries its own regulatory frame, claims standard, evidence expectation, and consumer scrutiny — and consumer scrutiny in this category is high. Claims that read as supportive in one frame can read as drug claims in another. Positioning that sits comfortably as lifestyle in one channel can attract regulatory attention in the next. RGM provides senior input on where the product belongs, what it can credibly say, and what evidence the strategy actually needs.
The work draws on decades of operating experience leading regulatory, scientific, and innovation strategy across women's health and consumer healthcare. The goal is a position that is regulatorily defensible, scientifically credible, and commercially coherent — not three different stories that don't reconcile.
Founders and brand teams typically engage RGM here when a women's health product is being shaped and the team is deciding which regulatory frame it belongs in; when claims for a menopause, fertility, pelvic health, or hormone product need to be reconciled with the evidence on hand; when a brand is moving across categories (for example, adding a supplement to a device line, or a diagnostic to a drug line); or when investor or retailer scrutiny on claims has surfaced and the team needs a senior read on the gap.
A documented position on where the product fits in the U.S. regulatory landscape, what it can credibly claim, what evidence the claim set requires, and how the brand can sequence multiple products in the category without collapsing the regulatory story. Written for a leadership team, a board, or an investor without further translation.
More in This Pillar